<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01433458</url>
  </required_header>
  <id_info>
    <org_study_id>CRLX030A2101</org_study_id>
    <secondary_id>2011-001596-39</secondary_id>
    <nct_id>NCT01433458</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of RLX030 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Subjects</brief_title>
  <official_title>A Single-dose, Open-label Parallel Study to Assess the Pharmacokinetics of RLX030 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Control Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess the pharmacokinetics of RLX030 during and after administration in
      subjects with mild to severe hepatic impairment and matched healthy control subjects.

      20 to 24 patients and 20 to 24 healthy subjects will be enrolled.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the serum concentration-time curve from time zero to infinity (AUCinf)</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>Blood samples will be collected during screening, days 1 through 4 and then on Day 15 for the determination of serum concentrations of RLX030</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>Blood samples will be collected during screening, days 1 through 4 and then on Day 15 for the determination of serum concentrations of RLX030</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration at 24 hour (C24h) after administration</measure>
    <time_frame>Upto Day 15</time_frame>
    <description>Blood samples will be collected during screening, days 1 through 4 and then on Day 15 for the determination of serum concentrations of RLX030</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events, serious adverse events and death</measure>
    <time_frame>Day 15</time_frame>
    <description>Monitoring of adverse events, serious adverse events and death from screening to end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of the presence and quantification of anti-RLX030 antibodies</measure>
    <time_frame>Day 1 (prior to administration) and Day 15 end of study</time_frame>
    <description>Blood will be collected and serum analyzed for the presence of antiRLX030 antibodies. Anti-RLX030 antibodies will be evaluated in serum in a validated four-tiered assay approach</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time [MRT] of RLX030</measure>
    <time_frame>screening, days 1, 2, 3, 4 and 15</time_frame>
    <description>Blood samples will be collected during screening, days 1 through 4 and then on Day 15 for the determination of serum concentrations of RLX030</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half life (T ½) of RLX030</measure>
    <time_frame>screening, days 1, 2, 3, 4 and 15</time_frame>
    <description>Blood samples will be collected during screening, days 1 through 4 and then on Day 15 for the determination of serum concentrations of RLX030</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic clearance of RLX030 from serum (CL)</measure>
    <time_frame>screening, days 1, 2, 3, 4 and 15</time_frame>
    <description>Blood samples will be collected during screening, days 1 through 4 and then on Day 15 for the determination of serum concentrations of RLX030</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss)</measure>
    <time_frame>screening, days 1, 2, 3, 4 and 15</time_frame>
    <description>Blood samples will be collected during screening, days 1 through 4 and then on Day 15 for the determination of serum concentrations of RLX030</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>RLX030: Group 1 mild hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with mild hepatic impairment will receive a single IV 24 hour infusion of RLX030</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RLX030: Group 2 moderate hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with moderate hepatic impairment will receive a single IV 24 hour infusion of RLX030</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RLX030: Group 3 severe hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with severe hepatic impairment will receive a single IV 24 hour infusion of RLX030</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RLX030: Group 4 - healthy volunteers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive a single IV 24 hour infusion of RLX030. This group will consist of 3 sub-groups to match patients of groups 1, 2and 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RLX030A</intervention_name>
    <description>RLX030 is administered as a continuous 24 hour infusion</description>
    <arm_group_label>RLX030: Group 1 mild hepatic impairment</arm_group_label>
    <arm_group_label>RLX030: Group 2 moderate hepatic impairment</arm_group_label>
    <arm_group_label>RLX030: Group 3 severe hepatic impairment</arm_group_label>
    <arm_group_label>RLX030: Group 4 - healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  All subjects:

             • Female subjects must be of non-child bearing potential OR use an effective method of
             contraception and sexually active males must use a condom during intercourse while
             taking the drug and for 5 half-lives after stopping treatment

          -  Subjects with hepatic impairment:

               -  Subjects must have either mild, moderate or severe hepatic impairment

        Exclusion criteria:

          -  All subjects

               -  Hepatic impairment due to non-liver disease

               -  Use of other investigational drugs at time of enrollment

               -  History of malignancy of any organ system

               -  Donation or loss of 400 mL or more of blood or plasma within 8 weeks prior to
                  initial dosing

               -  Hemoglobin levels below 10.0 g/dL at screening or baseline

          -  Subjects with hepatic impairment:

               -  Presence of any non-controlled and clinically significant disease that could
                  affect the study outcome or that would place the patient at undue risk

               -  Treatment with any cytostatic drug, vasodilator, autonomic alpha blocker or B2
                  agonist

               -  Any surgical or medical condition other than hepatic impairment which might
                  significantly alter the distribution or excretion of drugs

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grunstadt</city>
        <zip>D-67269</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>115419</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2011</study_first_submitted>
  <study_first_submitted_qc>September 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2011</study_first_posted>
  <last_update_submitted>January 20, 2013</last_update_submitted>
  <last_update_submitted_qc>January 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic impairment</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>RLX030</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

